Is Fulgent Genetics, Inc. (FLGT) a Buy, Sell, or Hold?
NASDAQ : FLGT
Fulgent Genetics, Inc.
$21.01 USD
$0.55 (2.69%)
- Volume
- 186.52K
- Average Volume
- 446.29K
- Market Capitalization
- $596.7M
- P/E Ratio
- -8.83
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $31.04
- Year Low
- $13.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.31
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ming Hsieh |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | FLGT |
| CUSIP | 359664109 |
| CIK | 0001674930 |
| Web | https://www.fulgentgenetics.com |
| Phone | 626 350 0537 |
| Currency | USD |
| Employees | 1313 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.31 |
| Quick Ratio | 5.31 |
| Cash Ratio | 0.26 |
Sales & Book Value
| Annual Sales | $322.67M |
| Price / Sales | 1.86 |
| Cash Flow | -3.66 |
| Price / Cash Flow | -5.27 |
| Price / Book | 0.62 |
Price Target and Rating
| Average Stock Price Forecast | $15.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | 40.07% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.97 |
| Trailing P/E Ratio | -8.83 |
| PEG Ratio | 0.15 |
| P/E Growth | 0.15 |
| Net Income | -$60.51M |
| Net Margin | -23.04% |
| Pretax Margin | -25.88% |
| Return on Equity | -6.70% |
| Return on Assets | -6.38% |
Financials Score
| AltmanZ Score | 4.20 |
| Piotroski Score | 2.00 |
| Working Capital | 388.91M |
| Total Assets | 1.16B |
| Ebit | -82.72M |
| Market Cap | 588.18M |
| Total Liabilities | 112.22M |
Poll Results
About Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expans ... ion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
2026-07-13 17:36:34
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
2026-07-09 16:05:00
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.
Fulgent Presents Updated FID-007 Data at ASCO 2026
2026-06-01 19:00:00
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.
2026-05-22 15:14:00
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.
2026-05-21 17:03:00
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT).
2026-05-20 08:28:00
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent's executive officers and whether investor losses may be recovered under federal securities laws.
2026-05-08 09:43:00
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.
2026-05-04 07:00:00
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Frequently Asked Questions
-
What is the current Fulgent Genetics, Inc. (FLGT) stock price?
-
Fulgent Genetics, Inc.(NASDAQ:FLGT) stock price is $21.01 in the last trading session. During the trading session, FLGT stock reached the peak price of $31.04 while $13.46 was the lowest point it dropped to. The percentage change in FLGT stock occurred in the recent session was 2.69% while the dollar amount for the price change in FLGT stock was $0.55.
-
FLGT's industry and sector of operation?
-
The NASDAQ listed FLGT is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of FLGT?
-
Hanlin Gao FACMG | Chief Scientific Officer & Laboratory Director
Natalie Prescott | General Counsel & Chief Privacy Officer
Brandon Perthuis | Chief Commercial Officer
Elias Nyankojo | Chief Information Security Officer
Jakub Sram | Vice President of Business Development & Sales -
How many employees does FLGT have?
-
Number of FLGT employees currently stands at 1313. FLGT operates from 4978 Santa Anita Avenue, El Monte, CA 91780, US.
-
Link for FLGT official website?
-
Official Website of FLGT is: https://www.fulgentgenetics.com
-
How do I contact FLGT?
-
FLGT could be contacted at phone #626 350 0537 and can also be accessed through its website. FLGT operates from 4978 Santa Anita Avenue, El Monte, CA 91780, US.
-
How many shares of FLGT are traded daily?
-
The average number of FLGT shares traded daily for last 3 months was 446.29K.
-
What is the market cap of FLGT currently?
-
The market value of FLGT currently stands at $596.7M with its latest stock price at $21.01